Evidence map›Paper›PMID 27893955›Full record

Trial reportJournal of child and adolescent psychopharmacology2017

Using a Patient-Centered Outcome Measure to Test Methylphenidate Versus Placebo in Children with Autism Spectrum Disorder.

Lawrence Scahill, Karen Bearss, Rena Sarhangian, Christopher J McDougle, L Eugene Arnold, Michael G Aman, James T McCracken, Elaine Tierney, Scott Gillespie, Valentina Postorino and 1 more

Registry-linked trialAbstract readComparative StudyMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of child and adolescent psychopharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05916339 (Comparative Effectiveness of Pharmacologic Management of ADHD in Children and Youth With Autism Spectrum Disorder), which is not on this map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05916339 phase4recruitingnot on this mapstarted 2023, after this paper: background citation

Comparative Effectiveness of Pharmacologic Management of ADHD in Children and Youth With Autism Spectrum Disorder

TypeinterventionalSponsorDaniel CouryRan2023 to 2027Enrolled500ConditionsADHD, Autism Spectrum DisorderArmsRandomization to either Amphetamine (AMP) class of stimulant medication or Methylphenidate (MPH) class of stimulant medication, Randomization to either Alpha 2 agonist class of medication or alternate class of stimulant.
3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Review
  5. Article
  6. Review
  7. Observational
  8. Observational
  9. Review
  10. Drug development for Autism Spectrum Disorder (ASD): Progress, challenges, and future directions.European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology · 2021
    Review
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 8 institutions in 1 country.

Lawrence Scahill1 School of Medicine, Emory University , Atlanta, Georgia .
Karen Bearss1 School of Medicine, Emory University , Atlanta, Georgia .
Rena Sarhangian3 David Geffen School of Medicine, University of California Los Angeles , Los Angeles, California.
Christopher J McDougle4 Harvard Medical School, Massachusetts General Hospital , Boston, Massachusetts.
L Eugene Arnold6 Nisonger Center, Ohio State University , Columbus, Ohio.
Michael G Aman6 Nisonger Center, Ohio State University , Columbus, Ohio.
James T McCracken7 Division of Child Psychiatry, University of California at Los Angeles , Los Angeles, California.
Elaine Tierney8 Kennedy Krieger Institute , Baltimore, Maryland.
Scott Gillespie1 School of Medicine, Emory University , Atlanta, Georgia .
Valentina Postorino1 School of Medicine, Emory University , Atlanta, Georgia .
Benedetto Vitiello9 National Institute of Mental Health , Bethesda, Maryland.
Emory University · USThe Ohio State University Wexner Medical Center · USCenter for Autism and Related Disorders · USKennedy Krieger Institute · USMarcus (United States) · USMassachusetts General Hospital · USNational Institute of Mental Health · USUniversity of California, Los Angeles · US

Funding

Atlanta Clinical and Translational Science Institute (ACTSI) RenewalUL1TR000454 · NCATS · EMORY UNIVERSITY · PI STEPHENS, DAVID S · 2012 to 2016
$25.8M
Psychopharmacology of Autism and related DisordersK23MH068627 · NIMH · INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS · PI POSEY, DAVID J · 2003 to 2007
$838k
Drug Response in Pediatric PsychopharmacologyK24MH001805 · NIMH · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MCCRACKEN, JAMES T. · 2001 to 2005
$662k
NCATS NIH HHS UL1 TR000454NIDA NIH HHS N01MH80011NIMH NIH HHS K23 MH068627NIMH NIH HHS K24 MH001805
6 · The paper itself

Abstract

objectivesParent rating scales are commonly used to evaluate change in clinical trials. Despite advantages, these measures may not capture parental impression of the child's most salient problems. We examine the use of parent target problems (PTPs) in a randomized trial of methylphenidate (MPH) in children with autism spectrum disorder and symptoms of attention-deficit/hyperactivity disorder.

methodsThis multisite, 4-week, randomized crossover trial compared three dose levels (low, medium, and high) of MPH with placebo. At baseline, the independent evaluator (IE) asked parents to nominate the child's two biggest problems. For each problem, the IE and parent coconstructed a brief narrative of the behavior and the impact on family life. The IE and parents reviewed and revised the narratives at subsequent visits. A panel of four judges, blind to treatment condition, independently reviewed the narratives to rate change from baseline on a 9-point scale: 1, normal; 2, markedly improved; 3, definitely improved; 4, equivocally improved; 5, no change; 6, possibly worse; 7, definitely worse; 8, markedly worse; 9, disastrously worse. The mean of the four raters was compared with primary and key secondary ratings from the original study.

resultsTwo PTPs were recorded at baseline for 60 participants. The inter-rater reliability of the four judges across all PTPs and time points was excellent (intraclass correlation = 0.95). On the primary outcome measure (Aberrant Behavior Checklist Hyperactivity subscale), the medium and high-dose levels were superior to placebo. On the mean PTP rating, only the high dose was superior to placebo. We also compared PTP cutoff scores 3.0 (definitely improved), 3.25, and 3.5 with the rate of positive response on the Improvement item of the Clinical Global Impressions scale in the original study. Sensitivities ranged from 68% to 88%.

conclusionsThe parent target problem method offers a systematic way to identify and track patient-centered outcomes.

Indexed as

Attention Deficit Disorder with HyperactivityAutism Spectrum DisorderCentral Nervous System StimulantsChildChild, PreschoolCross-Over StudiesDose-Response Relationship, DrugDouble-Blind MethodFemaleHumansMaleMethylphenidateParentsPatient Outcome AssessmentPsychiatric Status Rating ScalesReproducibility of ResultsCentral Nervous System StimulantsMethylphenidateautism spectrum disorderdouble-blind methodmethylphenidatepatient-centered outcomes

Identifiers

PMID27893955
PMCPMC5367913
OpenAlexW2557292717

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.